FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 20:41:17 07/06/2024 BST | ||
| 7.13 EUR | +11.06% |
|
| Current month | +45.21% | ||
| 1 month | +80.96% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 7.13 | +11.06% |
| 06/06/24 | 6.42 | +3.55% |
| 05/06/24 | 6.2 | +6.53% |
| 04/06/24 | 5.82 | +18.29% |
| 03/06/24 | 4.92 | +0.20% |
Delayed Quote Deutsche Boerse AG
Last update June 07, 2024 at 08:41 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SB1M1H |
| ISIN | DE000SB1M1H2 |
| Date issued | 17/06/2020 |
| Strike | 428.6 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 1.34 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.87 € |
|---|---|
| Lowest since issue | 0.13 € |
| Spread | 0.28 € |
| Spread % | 3.81% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat